Wilson Therapeutics

Wilson Therapeutics: Focused on rare diseases. Expects to advance WTX101, a novel first-in-class copper-protein-binding agent for treatment of Wilson Disease into pivotal Phase 3 FOCuS study in early 2018; granted OD in US/EU and FDA fast track status. WTX101 also granted OD for ALS in US; plan to investigate in SOD-1 mutated ALS.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Europe, Public
Market Cap
500MM - 1B
Website:
Address:
Kungsgatan 3
Stockholm, SE-111 43
Sweden

Company Participants at Carnegie Nordic Healthcare Day

Jonas Hansson
Wilson Therapeutics, CEO
Chief Executive Officer since 2012. Education: M.Sc. in pharmacy, Uppsala University and MBA, Stockholm School of Economics. Other current assignments: Venture Partner of HealthCap VI GP SA and HealthCap VII GP SA. Previous assignments (last five years): Board member of ReVENT Medical, Inc.
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.